The Latest Breaking News from Advarra

Icon Q4 Earnings Call Highlights

Icon (NASDAQ:ICLR) executives used the company’s latest earnings call to address the results of an accounting investigation, outline fourth-quarter and full-year 2025 performance, and provide guidance for 2026 amid what management described as near-term revenue and margin headwinds. Chief Executive

MarketBeat · May 28

In drug trials, lack of oversight of research ethics boards could put Canadian patients at risk

New drug approvals by Health Canada are based on the results of clinical trials. But before clinical trials can go ahead, they need to be approved by ethics committees known as Research Ethics Boards (REBs).

The Conversation · Oct 29, 2025

Do IBCs benefit biomedical research?

Experts say IBCs are a crucial tool for ensuring the safety of biomedical research. Critics say they are too opaque

Salon · Apr 7, 2022